Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

  • Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31. doi: 10.1128/AAC.00830-15.
Amabel Lapuebla  1 ,  Marie Abdallah  1 ,  Olawole Olafisoye  1 ,  Christopher Cortes  2 ,  Carl Urban  2 ,  David Landman  1 ,  John Quale  3
Affiliations
  • 1. Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
  • 2. Dr. James J. Rahal, Jr., Division of Infectious Diseases, New York Hospital Queens, Flushing, New York, USA.
  • 3. Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA [email protected].
PMID: 26014931 DOI: 10.1128/AAC.00830-15
Abstract

Imipenem with relebactam was active against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp., including K. pneumoniae carbapenemase (KPC)-producing isolates. Loss of OmpK36 in KPC-producing K. pneumoniae isolates affected the susceptibility of this combination. Enhanced activity was evident against Pseudomonas aeruginosa, including isolates with depressed oprD and increased ampC expression. However, the addition of relebactam to imipenem did not provide added benefit against Acinetobacter baumannii. The combination of imipenem with relebactam demonstrated activity against KPC-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa.

Products